Role of Oral SERDs in Treatment of ER+/HER2- in Metastatic Breast Cancer

Dr Vidula and Dr Langer review the role of oral selective estrogen receptor degraders (SERDs) in the treatment of ER+/HER2- metastatic breast cancer and what patient populations would benefit the most from treatment with oral SERDs.

Related Keywords

,Breast Cancer ,Metastatic Breast ,Estrogen Receptors Degraders ,Serds ,Iserd ,Er Her2 Metastatic Breast Cancer ,Endocrine Therapy ,Adjuvant Setting ,Approval Of Cdk Inhibitors ,